Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity-Reference-Cited by-同舟云学术

Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity

Published:2019-05-24 Issue:6 Volume:2019 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Verhoef Lise M¹,van den Bemt Bart JF²³,van der Maas Aatke¹,Vriezekolk Johanna E¹,Hulscher Marlies E⁴,van den Hoogen Frank HJ¹⁵,Jacobs Wilco CH⁶,van Herwaarden Noortje¹,den Broeder Alfons A¹⁵

Affiliation:

1. Sint Maartenskliniek; Department of Rheumatology; Hengstdal 3 Nijmegen Gelderland Netherlands 6574 NA

2. Sint Maartenskliniek; Department of Pharmacy; Hengstdal 3 Nijmegen Gelderland Netherlands 6522JV

3. Radboud University Medical Center; Department of Pharmacy; Nijmegen Netherlands

4. Radboud Institute for Health Sciences, Radboud University Medical Center; IQ healthcare; PO Box 9101 117 KWAZO Nijmegen Netherlands 6500 HB

5. Radboud University Medical Center; Department of Rheumatology; Nijmegen Netherlands

6. The Health Scientist; Fraeylemastraat 13 The Hague Netherlands 2532 TX

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010455.pub3/epdf/full

Reference118 articles.

1. Clinical evaluation usefulness of standardized protocol strategies of dose reduction in patients with rheumatoid arthritis in clinical remission treated with biologic therapies. The OPTIBIO study [abstract];Bejerano;Arthritis and Rheumatology,2016

2. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission;Chatzidionysiou;RMD Open,2016

3. Multicenter, randomised, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients is stable clinical remission;Chatzidionysiou;Arthritis and Rheumatism,2012

4. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission;Miedany;Clinical Rheumatology,2016

5. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a step-down strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial);Fautrel;Annals of Rheumatic Disease,2013

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial;RMD Open;2024-08

2. Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial;Rheumatology International;2024-07-24

3. Deprescribing: An umbrella review;Acta Pharmaceutica;2024-05-30

4. Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial;RMD Open;2024-04

5. Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?;Clinical Rheumatology;2024-03-05